An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis

A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis

(2018) Joseph M. Parker et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Longitudinal outcomes of patients enrolled in a phase Ib clinical trial of the adipose-derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis

(2018) Paschalis Ntolios et al.   Clinical Respiratory Journal

Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis

(2017) Mirjam J.G. van Manen et al.   EUROPEAN RESPIRATORY JOURNAL

Idiopathic pulmonary fibrosis

(2017) Luca Richeldi et al.   LANCET

Thyroid hormone inhibits lung fibrosis in mice by improving epithelial mitochondrial function

(2017) Guoying Yu et al.   NATURE MEDICINE

CXCL14 is a candidate biomarker for Hedgehog signalling in idiopathic pulmonary fibrosis

(2017) Guiquan Jia et al.   THORAX

Effectiveness of pulmonary rehabilitation in patients with interstitial lung disease of different etiology: a multicenter prospective study

(2017) Roberto Tonelli et al.   BMC Pulmonary Medicine

Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study

(2017) Jose D Herazo-Maya et al.   Lancet Respiratory Medicine

A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial

(2017) Surinder S Birring et al.   Lancet Respiratory Medicine

Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities

(2017) Christopher S King et al.   Lancet Respiratory Medicine

Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis

(2017) Steven D Nathan et al.   Lancet Respiratory Medicine

Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial

(2017) Ganesh Raghu et al.   Lancet Respiratory Medicine

Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?

(2017) Kerri A Johannson et al.   Lancet Respiratory Medicine

Idiopathic pulmonary fibrosis

(2017) Fernando J. Martinez et al.   Nature Reviews Disease Primers

Effect of the lung allocation score on lung transplantation in the United States

(2016) Thomas M. Egan et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value

(2016) Wim A. Wuyts et al.   LUNG

Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS® trials

(2016) Luca Richeldi et al.   RESPIRATORY MEDICINE

Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis

(2016) Steven D Nathan et al.   THORAX

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume

(2016) Martin Kolb et al.   THORAX

Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study

(2016) Karina Raimundo et al.   BMC Pulmonary Medicine

Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis

(2016) Michael Kreuter et al.   Lancet Respiratory Medicine

An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline

(2015) Ganesh Raghu et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Development of Novel Agents for Idiopathic Pulmonary Fibrosis

(2015) Thomas G. O'Riordan et al.   CHEST

Strategies targeting the IL-4/IL-13 axes in disease

(2015) Richard D. May et al.   CYTOKINE

Where do we go from here? Clinical drug development in idiopathic pulmonary fibrosis

(2015) Harold R. Collard   EUROPEAN RESPIRATORY JOURNAL

αvβ6 integrin may be a potential prognostic biomarker in interstitial lung disease

(2015) Gauri Saini et al.   EUROPEAN RESPIRATORY JOURNAL

The clinical effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: a systematic review and economic evaluation

(2015) Emma Loveman et al.   HEALTH TECHNOLOGY ASSESSMENT

The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Lung and Heart-Lung Transplantation Report—2015; Focus Theme: Early Graft Failure

(2015) Roger D. Yusen et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

A consensus document for the selection of lung transplant candidates: 2014—An update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation

(2015) David Weill et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

Mortality on the Waiting List for Lung Transplantation in Patients with Idiopathic Pulmonary Fibrosis: A Single-Centre Experience

(2015) David Bennett et al.   LUNG

Long-Term Effects of a 12-Week Exercise Training Program on Clinical Outcomes in Idiopathic Pulmonary Fibrosis

(2015) Baruch Vainshelboim et al.   LUNG

Pirfenidone for Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis

(2015) Carlos Aravena et al.   PLoS One

Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts

(2014) Enrico Conte et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis

(2014) Takashi Ogura et al.   EUROPEAN RESPIRATORY JOURNAL

Fibrotic extracellular matrix activates a profibrotic positive feedback loop

(2014) Matthew W. Parker et al.   JOURNAL OF CLINICAL INVESTIGATION

Unknown

(2014) Ye Cui et al.   MOLECULAR MEDICINE

A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

(2014) Talmadge E. King et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

(2014) Luca Richeldi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism

(2014) Alexandra Zanin-Zhorov et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Exercise Training-Based Pulmonary Rehabilitation Program Is Clinically Beneficial for Idiopathic Pulmonary Fibrosis

(2014) Baruch Vainshelboim et al.   RESPIRATION

A phase 1b study of placenta-derived mesenchymal stromal cells in patients with idiopathic pulmonary fibrosis

(2014) Daniel C. Chambers et al.   RESPIROLOGY

Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature

(2014) Kristin D Kistler et al.   BMC Pulmonary Medicine

Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study

(2014) MeiLan K Han et al.   Lancet Respiratory Medicine

Pathogenesis of Idiopathic Pulmonary Fibrosis

(2013) Paul J. Wolters et al.   Annual Review of Pathology-Mechanisms of Disease

Plasma B Lymphocyte Stimulator and B Cell Differentiation in Idiopathic Pulmonary Fibrosis Patients

(2013) J. Xue et al.   JOURNAL OF IMMUNOLOGY

A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis

(2013) Argyris Tzouvelekis et al.   Journal of Translational Medicine

PI3K p110γ overexpression in idiopathic pulmonary fibrosis lung tissue and fibroblast cells: in vitro effects of its inhibition

(2013) Enrico Conte et al.   LABORATORY INVESTIGATION

Recombinant human serum amyloid P in healthy volunteers and patients with pulmonary fibrosis

(2013) M.R. Dillingh et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Effect of ambulatory oxygen on exertional dyspnea in IPF patients without resting hypoxemia

(2013) Osamu Nishiyama et al.   RESPIRATORY MEDICINE

Epidemiology of idiopathic pulmonary fibrosis

(2013) Brett Ley et al.   Clinical Epidemiology

TGF-β1 Induces Tissue Factor Expression in Human Lung Fibroblasts in a PI3K/JNK/Akt-Dependent and AP-1–Dependent Manner

(2012) Malgorzata Wygrecka et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial

(2012) Ludmila Shulgina et al.   THORAX

Burden of illness in idiopathic pulmonary fibrosis

(2012) Harold R. Collard et al.   JOURNAL OF MEDICAL ECONOMICS

An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management

(2011) Ganesh Raghu et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

(2011) Paul W Noble et al.   LANCET

Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis

(2011) Luca Richeldi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of PI3K Prevents the Proliferation and Differentiation of Human Lung Fibroblasts into Myofibroblasts: The Role of Class I P110 Isoforms

(2011) Enrico Conte et al.   PLoS One

A novel single-chain-Fv antibody against connective tissue growth factor attenuates bleomycin-induced pulmonary fibrosis in mice

(2011) XIHUA WANG et al.   RESPIROLOGY

PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis

(2010) J.S. Duffield et al.   DRUG NEWS & PERSPECTIVES

Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome

(2010) J. W. Song et al.   EUROPEAN RESPIRATORY JOURNAL

Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment

(2010) Vivian Barry-Hamilton et al.   NATURE MEDICINE

Serum Amyloid P Therapeutically Attenuates Murine Bleomycin-Induced Pulmonary Fibrosis via Its Effects on Macrophages

(2010) Lynne A. Murray et al.   PLoS One

Effects of a leukotriene B4 receptor antagonist on bleomycin-induced pulmonary fibrosis

(2009) T. Izumo et al.   EUROPEAN RESPIRATORY JOURNAL

Pirfenidone in idiopathic pulmonary fibrosis

(2009) H. Taniguchi et al.   EUROPEAN RESPIRATORY JOURNAL

Interleukin-13 and Its Receptors in Idiopathic Interstitial Pneumonia: Clinical Implications for Lung Function

(2009) Sung-Woo Park et al.   JOURNAL OF KOREAN MEDICAL SCIENCE

BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy

(2008) F. Hilberg et al.   CANCER RESEARCH

Hyper-responsiveness of IPF/UIP fibroblasts: Interplay between TGFβ1, IL-13 and CCL2

(2008) Lynne A. Murray et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Partial Inhibition of Integrin αvβ6 Prevents Pulmonary Fibrosis without Exacerbating Inflammation

(2007) Gerald S. Horan et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE